Heart failure drug shows promise for Non-Diabetics

NCT ID NCT07112274

Completed Disease control Sponsor: Damanhour University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study tested whether empagliflozin, a diabetes drug, can improve heart structure and function in 50 non-diabetic patients with heart failure with preserved ejection fraction. Participants took either empagliflozin or a placebo daily. Researchers measured heart stress markers to see if the drug helps reduce cardiac remodeling.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: empagliflozin (10 mg tablet once daily)
What this could lead to: If successful, this could point toward a new treatment option for heart failure patients who are not diabetic, potentially improving heart function and quality of life.
What could go wrong: This is a small, completed trial with only 50 participants, so results may not apply to everyone. The study measured biomarkers, not long-term outcomes, so real-world benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diastolic heart failure heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE

Contacts and locations

Locations

Rehab Hussein Werida

Damanhūr, Elbehairah, 31527, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.